Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in systemic sclerosis-associated interstitial lung disease
jRCTs031180373Completed
- Sponsor
- Health
- Start
- May 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of rituximab in pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD) and interstitial pneumonia, sponsored by Health. Primary endpoint: Lung function test. Started May 2012; status: completed.
02
Drugs
rituximab
03
Conditions
pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD)interstitial pneumonia
Beyond the preview
Go deeper on jRCTs031180373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180373.